Significant progress made in new COVID-19 vaccine developed by the team of Prof Salanti

About the CTAThe Clinical trial application (CTA) for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine was submitted to the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands last week. It is expected to be approved under a COVID-19 fast-track review progress. This can be seen as another significant milestone following the November 2020 announcement of the successful GMP manufacturing of the vaccine. ExpreS2ion expects to present preliminary clinical Phase I/IIa results before end of Q1 2021.         

STOCKHOLM, 13/01/2021 (informazione.news - comunicati stampa - scienza e tecnologia)

The Clinical trial application (CTA) for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine was submitted to the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands last week. It is expected to be approved under a COVID-19 fast-track review progress. This can be seen as another significant milestone following the November 2020 announcement of the successful GMP manufacturing of the vaccine. ExpreS ion expects to present preliminary clinical Phase I/IIa results before end of Q1 2021.         

Since March 2020 , Attana has been assisting the team of Prof. Ali Salanti at the University of Copenhagen in the development of this COVID-19 vaccine with two of Attana's QCM Biosensors combined with research intelligence. As can be seen in the paper published, Attana's technology has foremost been used to analyze kinetic interactions between RBD antigens and CLP-RBD to hACE2. Furthermore, Attana and ExpreS ion recently established a strategic partnership including a supply agreement of proteins. In addition, Attana technology has been used to quality control the vaccine for the IND submission.

Teodor Aastrup
teodor.aastrup@attana.com
+46 (0) 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of   characterization of molecular interactions mimicking   conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.se or contact sales@attana.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/attana/r/significant-progress-made-in-new-covid-19-vaccine-developed-by-the-team-of-prof-salanti,c3267204

The following files are available for download: